Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms
of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that
of Avastin® (pharmacokinetics is nested in this study for Indian patients).